This month: AB569 Bactericidal Agent
What is AB569?
It’s a topical drug that is a combination of acidified nitrite and ethylenediaminetetraacetic acid. It was patented in 2018 by Daniel Hassett, a professor in the department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati College of Medicine.
What does it do?
Hassett’s research has found that AB569 kills virtually all pathogenic bacteria tested with no observed acquired resistance.
Has it been in the news?
Yes, it has. Research from the University of Cincinnati College of Medicine shows that it promotes killing of antibiotic-resistant bacteria while enhancing the healing of wounds in a variety of burn injuries.
How does it work?
Hassett said the research shows AB569 acts synergistically to kill all human burn wound strains of pathogens in vitro.
Anything else?
Yes, topical application significantly increases the anti-inflammatory mediators, it is claimed, allowing improved epidermal restoration and a more efficient healing process.
What would it be used for?
It was initially seen as a treatment for antibiotic-resistant organisms that cause pulmonary infections in patients with cystic fibrosis and chronic obstructive pulmonary disease, but the new research indicates it could be effective in addressing infections related to severe burns, urinary tract disorders, endocarditis and diabetes.
Where can I read more?
In the journal Infection and Immunity – bit.ly/3piGX5L
Image credit | Shutterstock